Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.
The company is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -1.68 Decreased by -31.86% | - |
| Mar 22, 24 | -26.60 Decreased by -144.25% | 3.80 Decreased by -800.00% |
| Nov 9, 23 | -1.29 Increased by +7.79% | - |
| Aug 15, 23 | -0.70 Decreased by -139.08% | - |
| May 15, 23 | -1.27 Decreased by -227.09% | - |
| Mar 31, 23 | -10.89 Decreased by -1.19 K% | -0.11 Decreased by -9.80 K% |
| Nov 10, 22 | -1.40 Increased by +36.36% | 0.20 Decreased by -800.00% |
| Aug 9, 22 | 1.80 Increased by +1.16 K% | -2.60 Increased by +169.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.07 M Increased by +77.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 166.03 K Increased by +N/A% | -1.23 M Increased by +94.36% | Decreased by -739.09% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.27 M Increased by +52.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.68 M Decreased by -225.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.76 M Decreased by -404.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -21.74 M Decreased by -2.20 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -21.49 M Decreased by -217.44% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 2.94 M Increased by +132.43% | Increased by +N/A% Decreased by N/A% |